Exakte Wirkstoffkennungen und zitierbare Passagen zu Wechselwirkungen, Gegenanzeigen und Nebenwirkungen.
Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
Neurological disorders (such as cerebellar symptoms, diplopia, lateral nystagmus, psychomotor
slowdown, hand movements and axial hypotonia) have been observed in children who had been
voluntarily prescribed more than 2.5 times the maximum recommended dose of 100 mg/kg/day for
several years. Episodes of hypotonia, instability, inability to walk, and hypertonia with inability of
limb movement, have been reported in children in the post-marketing setting with standard doses of
deferiprone. The neurological disorders progressively regressed after deferiprone discontinuation (see
sections 4.4 and 4.9).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
The safety profile of combination therapy (deferiprone and deferoxamine) observed in clinical studies,
post-marketing experience or published literature was consistent with that characterised for
monotherapy.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Data from the pooled safety database from clinical studies (1 343 patient-years exposure to Ferriprox
monotherapy and 244 patient-years exposure to Ferriprox and deferoxamine) showed statistically
significant (p<0.05) differences in the incidence of adverse reactions based on System Organ Class for
“Cardiac disorders", "Musculoskeletal and connective tissue disorders” and "Renal and urinary
disorders". The incidences of “Musculoskeletal and connective tissue disorders” and "Renal and
urinary disorders" were lower during combination therapy than monotherapy, whereas the incidence of
“Cardiac disorders" was higher during combination therapy than monotherapy. The higher rate of
“Cardiac disorders" reported during combination therapy than monotherapy was possibly due to the
higher incidence of pre-existing cardiac disorders in patients who received combination therapy.
Careful monitoring of cardiac events in patients on combination therapy is warranted (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
The incidences of adverse reactions experienced by 18 children and 97 adults treated with combination
therapy were not significantly different between the two age groups except in the incidence of
arthropathy (11.1% in children vs. none in adults, p=0.02). Evaluation of rate of reactions per
100 patient-years of exposure showed that only the rate of diarrhoea was significantly higher in
children (11.1) than in adults (2.0, p=0.01).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It
allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare
professionals are asked to report any suspected adverse reactions via the national reporting system
listed in Appendix V.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Version 2026-04-21T02:00:00Z · SHA-256 8d30ff208e2cac65daccef3e0bb072261a28975145087d11012d5a853f6fab1e · Passage 591ce3aa6d6555db7032d0551da929e990b92080da2928085827a75c666ec353 · Zeichen 6700–7014 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.